Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Interventional, Prospective IVD Device Study for the Testing of DNA Extracted from Tumor Tissue Biopsy Samples from Patients with Colorectal Cancer (CRC) Who Have Previously Tested Positive for KRAS G12C Mutation Into the Amgen Phase III Clinical Trial (Protocol No 20190172) to Demonstrate Clinical Performance of the Therascreen® KRAS RGQ PCR Kit.

NCT05347745 is registered in ClinicalTrials.gov with QIAGEN Gaithersburg, Inc as lead sponsor.

NCT NCT05347745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05347745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Interventional, Prospective IVD Device Study for the Testing of DNA Extracted from Tumor Tissue Biopsy Samples from Patients with Colorectal Cancer (CRC) Who Have Previously Tested Positive for KRAS G12C Mutation Into the Amgen Phase III Clinical Trial (Protocol No 20190172) to Demonstrate Clinical Performance of the Therascreen® KRAS RGQ PCR Kit.
Lead sponsor
QIAGEN Gaithersburg, Inc
Phase
Not applicable
Overall status
Completed
Start date
January 7, 2022
Completion date
April 30, 2023
Enrollment
219 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colo-rectal cancer